durvalumab,pembrolizumab,cisplatin,gemcitabine
merck,astrazeneca
['topaz-1', 'kn-966', '$mrk', '$azn']
full $mrk kn-966 data appear to come up short of $azn's marginal win in topaz-1. via from #aacr23 with comparison table 
Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.